icometrix

What icometrix does

icometrix is a Belgian medical-imaging AI company founded in 2011 in Leuven, Belgium, that develops the icobrain platform — FDA-cleared and CE-marked software that uses deep learning to automatically detect, segment, and quantify brain structures and lesions from MRI scans. The product portfolio spans disease-specific modules for multiple sclerosis (icobrain ms), Alzheimer's disease and dementia (icobrain dm), amyloid-related imaging abnormalities tied to anti-amyloid therapy safety monitoring (icobrain aria, the first FDA-cleared AI for ARIA detection), stroke, traumatic brain injury, epilepsy, Parkinson's disease, and brain tumors, plus the icobridge PACS/EMR integration middleware and the icompanion.ms patient-facing mobile medical device. The platform is deployed at 400+ hospitals across 30+ countries, with regulatory clearance in 28 countries, and is supported by >270 peer-reviewed scientific publications and a proprietary RECLAIM database holding >55,000 MRI scans from >7,500 MS patients.

The company generates revenue primarily through enterprise SaaS subscriptions to hospitals and academic medical centers for clinical icobrain deployment, and through clinical-trial and research-services engagements with pharmaceutical companies and research institutions using icobrain as a standardized imaging biomarker. Pricing is quotation-based and enterprise-negotiated on annual subscription terms; in the U.S. market, icobrain analysis is reimbursable through CPT-III codes 0865T/0866T processed by >30 insurers. Customer segments are diversified across three verticals — clinical hospitals and neurology/radiology departments, pharmaceutical and biotechnology companies running neurological clinical trials, and academic research institutions — with go-to-market executed via direct enterprise sales, medical-conference presence (RSNA, ECTRIMS, AAIC, ISMRM), and a network of strategic partnerships with medical societies and patient organizations.

In September 2025 GE HealthCare announced its intent to acquire icometrix, completing the transaction in November 2025; icometrix now operates as a wholly-owned GE HealthCare subsidiary, with the icobrain platform positioned to be distributed through GE's global MRI installed-base sales channel alongside ongoing direct enterprise relationships. Wim Van Hecke remains CEO.

Name

icometrix

Legal name

icometrix NV

Website

https://icometrix.com

Company type

Private

Founded year

2011

Operating status

Acquired

Headcount range

11–50 employees

Short description

icometrix develops FDA-cleared AI software (the icobrain platform) that automates brain MRI analysis for neurological disorders including multiple sclerosis, Alzheimer's disease, and stroke, serving 400+ hospitals across 30+ countries; acquired by GE HealthCare in November 2025.

Ownership category

akta.pro rank

Product category

AI Brain MRI Imaging Software

NAICS

Software Publishers (513210), Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Medical Imaging AI (HDAAAEAH)

Keywords

• Brain MRI analysis
• AI neuroimaging software
• Medical imaging AI
• Neurological diagnostics
• Radiology AI solutions

Headquarters

HQ city

Leuven

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Software licensing and subscriptions: icometrix generates revenue through licensing its FDA-cleared and CE-marked icobrain AI software to hospitals, research centers, and pharmaceutical companies. Fees are typically annual subscriptions with renewal terms, with pricing tied to usage volume or institutional agreements. The company also supports reimbursement through CPT-III codes 0865T/0866T for AI-assisted MRI analysis in the U.S. market.
2. Clinical trial and research services: Revenue generated from pharmaceutical companies and research institutions using icobrain technology for clinical trials, drug development studies, and real-world evidence generation in neurological conditions.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

icometrix develops and licenses the icobrain AI-powered brain imaging analysis platform, which automatically detects, segments, and quantifies brain structures and lesions from MRI scans across multiple neurological conditions including multiple sclerosis, Alzheimer's disease, ARIA monitoring, stroke, traumatic brain injury, epilepsy, Parkinson's disease, and brain tumors. The software is sold as annual subscriptions to hospitals, academic medical centers, research institutions, and pharmaceutical companies, complemented by icobridge for PACS/EMR integration and icompanion.ms as an FDA-cleared mobile app for MS patients.

Product overview

icometrix offers a unified AI-powered brain imaging platform centered on icobrain, with disease-specific modules including icobrain ms (multiple sclerosis), icobrain aria (Alzheimer's ARIA monitoring), and icobrain dm (dementia/Alzheimer's). The portfolio includes icobridge for PACS/EMR integration and icompanion.ms for patient engagement. All solutions are FDA-cleared, CE-marked, and validated across 400+ hospitals in 30+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• icobrain: AI-powered brain imaging analysis platform providing automated detection, segmentation, and quantification of brain structures and lesions to support clinicians and researchers in neurological disorders. Includes modules for MS (icobrain ms), dementia/Alzheimer's (icobrain dm), ARIA detection (icobrain aria), stroke, traumatic brain injury, epilepsy, Parkinson's disease, and brain tumors.
• icobridge
• icompanion.ms

Products and services

• icobrain AI-powered brain imaging analysis platform that automatically detects, segments, and quantifies brain structures and lesions from MRI scans to support clinical decision-making in neurology across multiple sclerosis, Alzheimer's, stroke, TBI, epilepsy, Parkinson's, and brain tumors.
• icobrain ms FDA-cleared and CE-marked MRI analysis solution for multiple sclerosis that provides lesion burden quantification, brain volume monitoring, and longitudinal comparison to support MS diagnosis and treatment decisions.
• icobrain aria FDA-cleared AI solution specifically designed to detect, measure, and grade amyloid-related imaging abnormalities (ARIA-E and ARIA-H) in patients receiving anti-amyloid Alzheimer's therapies, supporting safe treatment monitoring.
• icobrain dm

Quantifiable outcome

• 150% increase in detection of disease activity in MS
• +5 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered flagship and core.

• Multiple Sclerosis Association of America (MSAA)flagshipStrategic or Co-development Partner · 15 June 2026Partnership to expand MSAA's MRI Access Program, supporting approximately 1,000 MRI scans annually for individuals with MS experiencing financial or systemic barriers. icometrix provides AI-powered MRI analysis through icobrain ms technology for disease progression tracking and treatment effectiveness evaluation.
• AstraZenecacoreStrategic or Co-development Partner · 15 June 2026icometrix collaborates with AstraZeneca and MENACTRIMS on AI-driven initiative aiming to improve NMOSD (Neuromyelitis Optica Spectrum Disorder) diagnosis across the Middle East & Africa region.
• NVIDIAcoreTechnology or Integration · 20 November 2025Ongoing collaboration with NVIDIA as part of GE HealthCare's broader innovation partnerships to develop advanced imaging, AI-enabled diagnostics, and cloud-based solutions for healthcare.
• GE HealthCarecoreOthers · 10 September 2025GE HealthCare announced intent to acquire icometrix in September 2025 for undisclosed terms, completing the acquisition in November 2025. The deal integrates icometrix's icobrain AI platform with GE HealthCare's MRI systems to strengthen clinical decision support for neurological care, particularly Alzheimer's disease treatment monitoring.
• Charité - Universitätsmedizin BerlincoreStrategic or Co-development Partner · 1 September 2025Coordinator of the European CLAIMS project (Clinical Impact through AI-assisted MS Care) involving 15 organizations. icometrix provides quantitative MRI analysis of the >55,000 MRI scans in the RECLAIM database from >7,500 individuals with MS.
• ASST Papa Giovanni XXIIIcoreStrategic or Co-development Partner · 1 September 2025Italian public institution contributing clinical data, MRI scans and examinations from over 400 patients to the European RECLAIM research study on MS within the CLAIMS project. European Commission awarded budget of €200,000 for the project.
• American College of Radiology (ACR)flagshipStrategic or Co-development Partner · 2 April 2025ACR and icometrix entered strategic collaboration to improve quality of care for Alzheimer's disease patients. ALZ-NET participating imaging facilities receive discounted access to icobrain aria solution. Collaboration includes educational initiatives and standardized ARIA monitoring across the network.
• InRAD (International Registry for Alzheimer's Disease)flagshipStrategic or Co-development Partner · 3 March 2025Strategic collaboration to improve standardization of real-world evidence generation and care for Alzheimer's disease patients receiving disease-modifying therapies. Long-term objectives include integrating pseudonymized imaging outcomes into the InRAD registry for those using the icometrix pipeline.
• PhilipsflagshipTechnology or Integration · 21 November 2024Philips integrated icometrix AI solutions into its next-generation BlueSeal helium-free MRI system as part of its AI-enabled Smart Workflow solutions. Philips developed this partnership to offer cloud-based AI reading tools for neurological diagnostics alongside Quibim for prostate cancer diagnostics.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cortechs.ai: Direct competitor in AI-powered brain MRI analysis, with FDA-cleared NeuroQuant for brain volumetrics and similar disease modules (MS, Alzheimer's, TBI) sold to radiology departments of hospital systems.
• Viz.ai: AI radiology platform with neuro-focused modules (LVO stroke, aneurysm, PE) deployed across hospital systems, increasingly competing with icometrix in neurology AI workflows and the same enterprise radiology buyer.
• RapidAI: AI platform for neurovascular and stroke imaging with FDA-cleared modules overlapping icometrix's stroke and broader neurology offering, sold to the same hospital radiology and neurology customers.
• Aidoc: Enterprise radiology AI suite with multiple FDA-cleared modules including neuro (ICH, stroke); competes with icometrix for the same hospital enterprise imaging AI budget and PACS integration workflows.
• Quibim: AI medical imaging company with FDA-cleared QP-Prostate and broader MRI analysis modules; partner of Philips alongside icometrix and competes in the same imaging-AI category sold to hospital radiology.
• Blackford Analysis: Medical imaging AI platform offering a marketplace and curated AI applications for radiology, including neuro modules, serving the same hospital and enterprise imaging buyer.

Emerging players

• Annalise.ai: AI radiology platform with comprehensive chest and emerging neuro CT/MRI modules; addresses overlapping radiology workflows and competes for similar enterprise imaging AI contracts.
• Neosoma: AI software for brain tumor analysis and longitudinal monitoring on MRI — directly overlaps with icometrix's icobrain brain tumor module in the same neuro-oncology imaging workflow.
• Subtle Medical: AI imaging company focused on MRI image enhancement and workflow acceleration; adjacent to icometrix as it operates at the MRI acquisition stage and partners with similar hospital radiology customers and modality vendors.

Broad incumbents

• Brainlab: Larger established neuroimaging and surgical planning software provider with Elements software family; overlaps with icometrix in neuro quantitative imaging and broader neurology hospital software sales.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/icometrix
• YouTubeyoutube.com/user/icoMetrix
• LinkedInlinkedin.com/company/icometrix

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about icometrix